Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 7/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | THRA | P10827 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2865175 | 0.91 | TLR7 (0.38) | TLR7S1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL2860898 | 0.89 | TLR7 (0.40) | TLR7S1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL28765324 | 0.85 | TLR7 (0.50) | TLR7S1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL2868556 | 0.84 | ALPG (0.44) | SMN1; SMN2 | |
| SCHEMBL2871063 | 0.82 | TLR7 (0.39) | TLR7ENPP2SMN1; SMN2THRAAKT1 | |
| SCHEMBL2872112 | 0.80 | ESR1 (0.42) | TLR7S1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL2868462 | 0.79 | CSNK2A1 (0.44) | SMN1; SMN2THRAL3MBTL1AKT1THRB | |
| SCHEMBL2869183 | 0.77 | THRA (0.47) | ENPP2SMN1; SMN2THRATHRBCYP2C19 | |
| SCHEMBL2864769 | 0.76 | SLC5A2 (0.45) | ENPP2SMN1; SMN2CYP2C19 | |
| SCHEMBL2864893 | 0.74 | SLC5A1 (0.46) | TLR7S1PR2S1PR1S1PR3LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691898-B2 | Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | NR0B1, NR0B2, PTH1R | TLR7 2560/4885S1PR2 638/4885S1PR1 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.